HSBC reiterated its sell rating on Eli Lilly shares, citing over-inflated investor expectations for its weight-loss drug pipeline. The brokerage warned that aggressive pricing strategies for medications like Wegovy could trigger deeper price cuts, pressuring profit margins. This marks the second bearish stance from HSBC on Lilly in a year, signaling growing skepticism about the sustainability of high valuations for obesity treatments.

The stock tumbled 3% post-announcement, reflecting concerns that Lilly’s reliance on weight-loss drugs—already facing intense competition from rivals—may not justify current market expectations. Analysts argue that if competitors like Roche or Amgen undercut prices, Lilly could face margin compression, particularly as insurers demand lower costs for obesity therapies. This dynamic threatens to erode investor confidence in the company’s near-term growth trajectory.

While Lilly maintains that its drugs offer superior efficacy, the HSBC report underscores a broader industry shift: regulators and payers are pushing for affordability, which could force manufacturers to rethink pricing models. For Lilly, this means balancing innovation with accessibility—a challenge that may test its ability to maintain premium valuations in a sector increasingly prioritizing cost-effectiveness.

Investors now face a pivotal question: Can Lilly’s pipeline withstand price pressures without sacrificing R&D investment? The outcome will likely shape the competitive landscape of obesity therapeutics, where HSBC’s bearish bets highlight the fragility of current market darlings.